Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
	Jun. 25, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues [Abstract]
Total net revenue		$ 444,448	$ 408,830	$ 276,741
Cost of revenue		258,555	211,994	149,476
GROSS PROFIT		185,893	196,836	127,265
Operating expenses:
General and administrative		143,794	127,993	84,822
Research and development		8,229	8,487	3,001
Sales and marketing		47,862	47,350	29,402
Total operating expenses		199,885	183,830	117,225
(LOSS) INCOME FROM OPERATIONS		(13,992)	13,006	10,040
Interest expense, net		7,019	3,713	6,230
Other (income) expense, net		(11,861)	4,630	(14)
Loss on extinguishment of debt		1,400	1,018	0
Loss on termination of cash flow hedge		3,506	0	0
(Loss) income before taxes		(14,056)	3,645	3,824
Income tax (benefit) expense		(18,228)	(4,361)	1,184
NET INCOME		4,172	8,006	2,640
Deemed dividends on preferred stock and amortization of beneficial conversion feature		0	0	5,627
Gain on redemption of preferred stock	$ (9,100)	0	0	(9,075)
NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS		$ 4,172	$ 8,006	$ 6,088
Earnings Per Share, Basic and Diluted [Abstract]
Basic (in dollars per share)		$ 0.04	$ 0.08	$ 0.07
Diluted (in dollars per share)		$ 0.04	$ 0.08	$ 0.07
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)		108,579	100,470	85,618
Diluted (in shares)		111,794	103,615	91,568
Clinical Services
Revenues [Abstract]
Total net revenue		$ 382,337	$ 361,161	$ 241,873
Pharma Services
Revenues [Abstract]
Total net revenue		$ 62,111	$ 47,669	$ 34,868